Shai Mulinari
1 – 50 of 91
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Delays in dealing with complaints against drug companies are growing, BMJ finds
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Payments to healthcare organisations reported by the medical device industry in Europe from 2017 to 2019 : An observational study
(
- Contribution to journal › Article
-
Mark
Evaluating time to withdrawal of anti-cancer drug indications that received FDA's accelerated approval
2024) In QJM - Monthly Journal of the Association of Physicians(
- Contribution to journal › Letter
-
Mark
Patterns of company misconduct, recidivism, and complaint resolution delays : A temporal analysis of UK pharmaceutical industry self-regulation within the European context
2024) In Regulation and Governance(
- Contribution to journal › Article
-
Mark
Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States : A comparative study of accelerated approvals
(
- Contribution to journal › Article
-
Mark
Broken beyond repair: self regulation of industry payments to clinicians and hospitals
(
- Contribution to journal › Debate/Note/Editorial
- 2023
-
Mark
Conceptual unclarity about COVID-19 ethnic disparities in Sweden: Implications for public health policy
(
- Contribution to journal › Article
-
Mark
Race in clinical trials in Sweden: how regulatory and medical standards in clinical research trump the post-racial discourse
2023) In Sociology of Health & Illness(
- Contribution to journal › Article
-
Mark
International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency
(
- Contribution to journal › Article
-
Mark
Short-circuiting biology: Digital phenotypes, digital biomarkers, and shifting gazes in psychiatry
2023) In Big Data and Society(
- Contribution to journal › Article
-
Mark
Pharmaceutical industry payments to NHS trusts in England : A four-year analysis of the Disclosure UK database
(
- Contribution to journal › Article
-
Mark
Authors’ reply to Fell
(
- Contribution to journal › Letter
-
Mark
Unethical pharmaceutical marketing: a common problem requiring collective responsibility
(
- Contribution to journal › Article
- 2022
-
Mark
The making of a Swedish strategy : How organizational culture shaped the Public Health Agency's pandemic response
(
- Contribution to journal › Article
-
Mark
A “patient-industry complex”? Investigating the financial dependency of UK patient organisations on drug company funding
(
- Contribution to journal › Article
-
Mark
Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?
(
- Contribution to journal › Article
-
Mark
Capitalizing on transparency: commercial surveillance and pharmaceutical marketing after the Physician Sunshine Act
(
- Contribution to journal › Article
-
Mark
De unga gör helt rätt när de stämmer staten
2022) In Aftonbladet(
- Contribution to specialist publication or newspaper › Newspaper article
-
Mark
Content and strength of conflict of interest policies at Scandinavian Medical Schools: a cross sectional study
(
- Contribution to journal › Article
-
Mark
Advancing international comparison of pharmaceutical industry funding of patient advocacy: Focus on Denmark
(
- Contribution to journal › Article
-
Mark
“Black race”, “Schwarze Hautfarbe”, “Origine africaine”, or “Etnia nera”? The absent presence of race in European pharmaceutical regulation
2022) In BioSocieties(
- Contribution to journal › Article
-
Mark
Tip of the iceberg? Country- and company-level analysis of drug company payments for research and development in Europe
(
- Contribution to journal › Article
- 2021
-
Mark
Failure of responsive regulation? : Pharmaceutical marketing, corporate impression management and off-label promotion of enzalutamide in Europe
(
- Contribution to journal › Article
-
Mark
Pharmaceutical industry self-regulation and non-transparency : country and company level analysis of payments to healthcare professionals in seven European countries
(
- Contribution to journal › Article
-
Mark
Sweden
2021)(
- Chapter in Book/Report/Conference proceeding › Chapter in report
-
Mark
Data Transparency and Pharmaceutical Regulation in Europe : Road to Damascus, or Room without a View?
2021) p.63-94(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: A European policy review
(
- Contribution to journal › Article
-
Mark
Drug company payments to General Practices in England: cross-sectional and social network analysis
(
- Contribution to journal › Article
-
Mark
Is there evidence for the racialization of pharmaceutical regulation? : Systematic comparison of new drugs approved over five years in the USA and the EU
(
- Contribution to journal › Article
-
Mark
Sociologisk forskning om covid-19-pandemin : En introduktion
(
- Contribution to journal › Debate/Note/Editorial
- 2020
-
Mark
The will of Congress? Permissive regulation and the strategic use of labeling for the anti-influenza drug Relenza
(
- Contribution to journal › Article
-
Mark
Revisiting the pharmaceuticalisation of pandemic influenza using Lukes’ framework of power
(
- Contribution to journal › Article
-
Mark
Pharmaceutical lobbying and pandemic stockpiling : A feeling of déjà vu in the Nordic countries and why the sociological perspective is crucial to understand COVID-19
(
- Contribution to journal › Article
-
Mark
Sociologiska perspektiv på coronakrisen : Fyra sociologer om samhällets reaktion på covid-19
(
- Contribution to journal › Letter
-
Mark
Ras och genetiska skillnader : Introduktion till avsnittets texter
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016)
(
- Contribution to journal › Article
-
Mark
Bengt Olle Bengtsson intervjuad av Shai Mulinari : Om genetisk likhet och skillnad
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Ras i genetikens tidevarv
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Svenska gener? : Om stratifierad precisionsmedicin och genetikens etniska gränsdragningar
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Five years of pharmaceutical industry funding of patient organisations in Sweden: cross-sectional study of companies, patient organisations and drugs
2020) In PLoS ONE(
- Contribution to journal › Article
- 2019
-
Mark
Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK
(
- Contribution to journal › Article
-
Mark
Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015
(
- Contribution to journal › Article
-
Mark
Exposing drug industry funding of UK patient organisations
(
- Contribution to journal › Article
-
Mark
The whistleblowing drama behind Astellas’s suspension from the ABPI
(
- Contribution to journal › Letter
- 2018
-
Mark
Explaining biological depression theories
(
- Contribution to journal › Letter
-
Mark
Let the drugs lead the way! : On the unfolding of a research programme in psychiatry
(
- Contribution to journal › Article
-
Mark
Sociodemographic patterns in pharmacy dispensing of medications for erectile dysfunction in Sweden
(
- Contribution to journal › Article
-
Mark
Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries
(
- Contribution to journal › Article
-
Mark
Pharmaceutical lobbying and pandemic stockpiling of Tamiflu: a qualitative study of arguments and tactics
(
- Contribution to journal › Article
-
Mark
Categorical and anti-categorical approaches to US racial/ethnic groupings: revisiting the National 2009 H1N1 Flu Survey (NHFS)
(
- Contribution to journal › Article